This article is more than 5 years old. Information may no longer be current.

RestorGenex receives European patent for skin treatment RES-529

RestorGenex Corp. announced that the European Patent Office has issued the company a patent titled, “Compositions and Methods to Treat Skin Diseases Characterized by Cellular Proliferation and Angiogenesis.”

The patent, No. 2364700, focuses on RestorGenex’s candidate RES-529 for the prevention and treatment of skin diseases, as well as on the composition of matter of RES-529, according to a company press release.

RES-529 is a first-in-class allosteric dissociative TORC₁/TORC₂ inhibitor of the PI₃K pathway intended to be used for the treatment of diseases involving cell proliferation and angiogenesis.

RestorGenex’s intellectual property portfolio related to RES-529 also includes U.S. patent No. 8,475,776, which provides composition of matter and method of use protection in the United States, according to the release.

Reference: www.restorgenex.com.